We stand with Ukraine

Enhance Pharma Insights and Protection with AI Analysis

From innovation to regulation to patient engagement, we help life science and pharmaceutical organizations to gain the the most insights from all their information assets to improve R&D productivity, enhance the quality of treatment and care and prevent operational risks.

Expert.ai’s Life Science and Pharmaceutical solutions provides research, regulatory and knowledge teams with capabilities like:

  • Access to real-time data sources (public, subscription-based or private) under a unified semantic schema and taxonomy for specific therapies.
  • The ability to automatically analyze and validate specific scientific claims to see if they are confirmed, or not, against a set of trusted sources.
  • Customizable search results and dashboards that compare trusted life sciences resources with domain- specific Knowledge Graphs to identify new, relevant and valuable information for drug discovery.

Download the White PaperDownload the Datasheet

Key Opinion Leaders


UMLS Drugs and Interventions


UMLS Diseases



Life Science & Pharma Solution Areas

Drug Discovery

Automatically extract connections between biomedical entities in literature for in-depth causality analysis in support to researchers.


Learn More

Clinical Trial Insights

Monitor clinical trials and social media sources filtered by any combination of indication, drug, mechanism of action, sponsor or geography gain clinical trial insights.


Learn More

Scientific Publication Insight & Analysis

Scan the latest scientific and biopharma news on drug approvals, trials, conferences and more to ensure users get instant updates for their topics of interest.


Learn More

Regulatory Report Quality Reviews

Accelerate the quality control check processes of preclinical reports prior to their submission to regulatory bodies.


Learn More

Intellectual Property Protection

Review patent claims against claims in published papers and clinical trial activity automatically alerting to potential areas of infringement and/or licensing opportunities.